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INTRODUCTION
Sleep related alveolar hypoventilation (SRAH) is character-
ized by decreased alveolar ventilation resulting in sleep related 
oxygen arterial desaturation in patients with normal mechanical 
properties of the lung. SRAH can be distinguished from central 
and obstructive sleep apnea (OSA) by the fact that OSA is de-
fined by periodic alterations in the respiratory flow (i.e., apnea, 
hypopnea, or respiratory effort-related arousals [RERAs]) that 
are not typically present in SRAH, even though both conditions 
(sleep apnea and SRAH) may coexist.1
In the absence of pulmonary parenchymal or vascular pa-
thology, lower airway obstruction, neuromuscular disorders, or 
kyphoscoliosis, the disorder is referred to as idiopathic SRAH. 
When severe obesity is present, it predisposes individuals to 
developing SRAH by increasing the burden on disadvantaged 
respiratory muscles, and then the disorder can be referred to 
as obesity-related sleep hypoventilation syndrome, and is usu-
ally included in the spectrum of obesity-related hypoventilation 
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(pickwickian syndrome).2,3 Not all patients with SRAH have 
an increased body mass index (BMI), nor will all patients with 
obesity develop SRAH. The magnitude of obesity and SRAH 
is not sufficiently correlated to predict what will occur during 
sleep in individual patients.1
The chief feature of SRAH is reduced ventilation secondary 
to decreased tidal volume, resulting in hypercapnia, hypoxemia, 
and leading to a disruption of sleep architecture with increased 
fragmentation and awakenings. Hypoxemia may also give rise 
to arrhythmia during sleep.1
One of the simplest noninvasive methods to study changes 
in cardiovascular autonomic control is to measure heart rate 
variability (HRV), which can be defined as a physiologic phe-
nomenon where the time interval between heartbeats varies. It 
is measured by the variation in the beat-to-beat interval. HRV 
reflects the relationship between the parasympathetic nervous 
system (PNS) and the sympathetic nervous system (SNS), and it 
has been reported to be a good predictor for future cardiovascu-
lar disease.4 HRV can be analyzed by using a time- or frequency-
domain analysis in several intervals (see Methods section).
There is evidence supporting the fact that the autonomic 
nervous system is dysregulated during sleep and wakefulness 
in patients with OSA even without evidence of cardiovascu-
lar disease. When HRV is analyzed, patients with OSA exhibit 
increased sympathetic activity and decreased parasympathetic 
activity.5,6 The HRV improves after initiation of continuous pos-
itive airway pressure, even in the first night of treatment.7 How-
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ever, it remains unclear whether the changes in HRV seen in 
patients with OSA are a consequence of the hypoxemia during 
sleep or, conversely, are a result of the dramatic fluctuations in 
intrathoracic pressure that occur during the repetitive nocturnal 
respiratory events (i.e. apnea, hypopnea, or RERAs).
In this regard, patients with SRAH represent a uniquely 
valuable group of individuals to explore this question, as they 
have significant oxygen desaturations during sleep but respira-
tory events are almost absent. We hypothesized that, if HRV 
changes are a consequence of hypoxemia (and not an effect of 
the changes in intrathoracic pressure during respiratory events), 
spectral components of HRV should not differ between patients 
with SRAH and those with OSA.
According to the hypothesis previously mentioned, our aim 
in this study was to evaluate nocturnal autonomic cardiovascu-
lar function in patients with SRAH using frequency- and time-
domain HRV analysis during 1-night polysomnography (PSG) 
and compare it with that of patients with OSA and control 
patients. Further, we analyzed whether HRV changes differed 
depending on the different sleep stages (rapid eye movement 
[REM], N1-N2, N3, and wakefulness just before and after 
sleep), and whether HRV changes were correlated with any of 
the patients’ characteristics such as body mass index (BMI), 
minimal oxygen saturation (SatO2), mean SatO2, or wake time 
after sleep onset (WASO).
Previous studies analyzing HRV have been reported in con-
genital central hypoventilation syndrome (Ondine’s course)8,9 
and in hypoventilation associated with chest wall deformities 
and neuromuscular disease10; however, no studies have inves-
tigated the spectral HRV components across sleep stages in pa-
tients with idiopathic or obesity-related SRAH in comparison 
with patients with OSA or healthy control patients. An under-
standing of the changes in HRV during sleep in patients with 
SRAH may offer insights into the physiopathology of the au-
tonomic nervous system disruption seen in patients with sleep 
related breathing disorders.
METHODS
Patients
This was a single-center cross-sectional study involving pa-
tients with idiopathic SRAH and obesity-related SRAH. For 
each patient with SRAH, a patient with OSA matched by age, 
sex, BMI, minimal SatO2, and mean SatO2 was selected. Con-
trol patients with a normal PSG study were also matched in 
age, sex, and BMI to the remaining two groups and matched in 
apnea-hypopnea index (AHI) with patients with SRAH.
Patients were retrospectively selected from the sleep da-
tabase of the Sleep Unit of the University Clinic of Navarra. 
Patients were either referred to the Sleep Unit from other de-
partments within the University Clinic of Navarra (neurology, 
pulmonology, endocrinology, ear, nose, and throat, etc.) or from 
other hospitals of Spain. Most patients were referred because 
of primary complaints of poor nocturnal sleep, daytime sleepi-
ness, morning headache, or other symptoms suggesting a sleep 
related breathing disorder. Before PSG studies, all patients 
completed a questionnaire to document clinically relevant data 
including current medications, current medical problems, al-
cohol, tobacco, and recreational drugs consumption, Epworth 
Sleepiness Scale score, height, and weight. During each hos-
pitalization, sitting systolic and diastolic blood pressures (SBP 
and DBP) were measured using a mercury sphygmomanometer 
just before the PSG study. Physical and neurologic examina-
tions were performed to exclude other pathologies.
Inclusion criteria for patients with SRAH were (1) PSG 
showing more than 30% of total sleep time at an SatO2 of less 
than 90%; (2) five or fewer scoreable respiratory events (i.e. 
apnea or hypopnea) per hour of sleep; (3) absence of periodic 
alterations of air flow; (4) absence of kyphoscoliosis and pul-
monary, neurologic, muscular, or cardiac cause.
Inclusion criteria for patients with OSA were (1) five or more 
scoreable respiratory events (i.e. apnea or hypopnea) per hour 
of sleep; (2) evidence of respiratory effort during all or a por-
tion of each of the respiratory events; (3) matching with patients 
with SRAH in terms of BMI, age, sex, minimal SatO2, and mean 
SatO2.
Inclusion criteria for control patients were (1) five or fewer 
scoreable respiratory events (i.e. apnea or hypopnea) per hour 
of sleep; (2) PSG showing more than 30% of total sleep time 
at an SatO2 of more than 90%; (3) matching with patients with 
SRAH in terms of BMI, age, sex, and AHI.
Exclusion criteria for the three groups were (1) atrial fibril-
lation and other cardiac arrhythmias; (2) myocardial ischemia, 
cardiomyopathy or myocardial infarction; (3) cardiac pace-
maker; (4) history of neurologic or psychiatric disorders; (5) 
thyroid diseases; (6) other sleep disorders such as periodic limb 
movement disorder, restless limb syndrome, or narcolepsy; (7) 
treatment with calcium channels blocker, beta-blockers, or any 
other drugs known to affect the autonomic nervous system; 
and (8) a previous diagnosis of congenital central hypoventila-
tion syndrome.
Data Acquisition and Handling
OSA and SRAH were diagnosed based on an overnight PSG 
study. PSG studies were performed using Lamont amplifiers, 
20 bit, 32 channels, and dedicated inputs for electroencephalo-
gram, tibial and chin electromyogram, oronasal flow, respira-
tory effort, oxymetry, heart rate, and body position. Sleep stage 
classification was performed following the current American 
Academy of Sleep Medicine (AASM) criteria,11 and hypop-
neas, apneas, and arousals were scored using the standard rec-
ommended AASM scoring criteria.1 We recorded data on the 
following features: total sleep time, percentage of sleep spent 
in REM, N1-N2, and N3; REM latency; WASO; number of 
periodic leg movements per hour; number of awakenings per 
hour; SatO2; minimal SatO2; number of oxygen desaturations 
per hour of sleep; and AHI.
HRV Data Handling and Analysis
For each patient, we carefully selected several consecutive 
apnea-free, arousal-free, 10-min electrocardiogram (ECG) 
samples, from each sleep stage (REM, N1-N2, N3 and wake-
fulness before sleep [W-pre] and after sleep [W-post]). ECG 
was recorded with two derivations (V3 and V5), amplified, 
band-pass filtered (0.3-30 Hz), and digitized at 250 Hz. The 
beat series derived from the ECG segments was interpolated 
and resampled, using cubic splines, to obtain equally spaced 
RR intervals with an interpolation rate of 4 Hz.
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Sleep data in the form of digital files were collected us-
ing the Stellate Reviewer software program (Harmonie 6.0). 
The sleep segments were saved as text files from their digital 
recording in Stellate Reviewer Version 6 (Stellate Inc., Mon-
treal, Canada). The text files containing the sleep data were 
converted into a Spike2 data file (S2R) using Spike2 (ver-
sion 6.02, Cambridge Electronic Design Limited, Cambridge, 
UK). Then, two of the authors (JAP, EU) assessed HRV of 
each patient blinded to the PSG results using the S2R files 
in a HRV analysis program created with MatLab (Mathworks 
Inc., Nattick, MA, USA) by one of the authors (JLA). Each 
ECG recording was manually inspected to avoid abnormal 
QRS wave morphology, ectopic cardiac beats, and movement 
artifacts, and to ensure that R-waves were correctly marked 
by the HRV analysis program to allow an accurate detection 
of R-R intervals.
The following HRV measures were computed in the time and 
frequency domain based on the measurement standards12:
Time Domain Measures
• Mean R-R: the mean normal-to-normal RR interval, in ms.
• The standard deviation of normal-to-normal RR interval 
(SDNN), reflecting the overall HRV, in ms.
Frequency Domain Measures
For HRV analysis in the frequency domain, RR time series 
were interpolated at 250 ms to obtain equidistant values. Then, 
fast Fourier transform was applied. We quantified HRV power 
in four frequency bands that have been associated with different 
physiologic rhythms4:
• Ultra low frequency (ULF) band (ULF power in the 
range of 0.0001 to 0.003 Hz), in ms2, which is associated 
with circadian variation, and variations in the activity of 
neuroendocrine system.
• Very low frequency (VLF) band (VLF power in the 
range of 0.003 to 0.04 Hz), in ms2, which reflects vagal 
and renin-angiotensin system effects on heart rate.
• Low frequency (LF) band (LF power in the range of 
0.04 to 0.15 Hz), in ms2, which reflects a combination 
of sympathetic and parasympathetic influences and 
baroreflex function.13
• High frequency (HF) band (HF power in the range 
of 0.15 to 0.40 Hz), in ms2, which primarily reflects 
parasympathetic activity.
• We also considered the LF/HF ratio, a unitless measure 
thought to reflect sympathovagal balance or sympathetic 
modulations.12
Statistical Analyses
Comparisons of patients’ characteristics and sleep charac-
teristics in the three samples were made. The effect of sleep 
on the HRV variables across sleep stages and within the same 
sleep stage among the three groups was calculated by using 
analysis of variance (ANOVA), with Bonferroni correction 
for multiple comparisons, and the interaction where appropri-
ate. The correlation between the clinical parameters of SRAH 
patients and the various measures of HRV was analyzed with 
Spearman correlation coefficient. In all cases, statistical sig-
nificance was defined as P < 0.05. All statistical tests were 
performed using SPSS version 15.0.1 (SPSS Inc., Chicago, 
IL, USA).
Standard Protocol Approval
This study was approved by the Institutional Review Board 
(IRB) of the University of Navarra. The IRB specifically waived 
the need for consent of participants, as this was a retrospective 
study. Data were made anonymous by removal of direct identi-
fiers from the data file (a variable was removed when it was 
highly identifying such as name, surname, or place of birth; 
other variables irrelevant for analyses were also removed).
RESULTS
Sample Characteristics
Fifteen female patients with SRAH who fulfilled the inclu-
sion criteria were selected. Fifteen female patients with OSA 
and 15 female control patients were also selected. All groups 
had similar age, BMI, and tobacco, alcohol, and caffeine intake 
levels. Eleven patients with SRAH had severe obesity (BMI 
≥ 30 kg/m2), fulfilling criteria for obesity hypoventilation syn-
drome; the remaining four patients had a BMI ≤ 25 kg/m2, ful-
filling criteria for idiopathic SRAH. Characteristics of patients 
Table 1—Sample characteristics
SRAH (n = 15) OSA (n = 15) Controls (n = 15) P
Age (y), mean ± SD 45.93 ± 11.56 51.35 ± 15.48 46.22 ± 12.01 0.51
Females, n (%) 15 (100%) 15 (100%) 15 (100%) 1.00
Postmenopausal, n (%) 9 (60%) 10 (66.6%) 9 (60%) 0.67
BMI (kg/m2), mean ± SD 37.03 ± 10.52 35.63 ± 10.18 36.91 ± 11.06 0.82
Blood pressure (mm Hg), mean ± SD
Systolic 122.36 ± 7.67 123.31 ± 15.29 119.59 ± 14.02 0.12
Diastolic 76 ± 6.92 75.54 ± 9.08 72.72 ± 8.18 0.31
Tobacco (cigarettes/day) 7.12 ± 10.23 13 ± 10.17 10 ± 16.27 0.25
Alcohol (U/day) 0.5 ± 0.9 1.1 ± 0.2 0.6 ± 0.2 0.43
Caffeine (100-mg dose/day) 2.6 ± 0.7 2.5 ± 1.2 2.6 ± 0.9 0.84
BMI, body mass index; OSA, obstructive sleep apnea; SD, standard deviation; SRAH, sleep related alveolar hypoventilation.
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with SRAH, patients with OSA, and control patients are sum-
marized in Table 1.
Sleep structure was similar in all groups, including REM la-
tency, percentage of REM, N1-N2 and N3 sleep, and periodic 
limb movement index. As expected, patients with OSA had a 
higher AHI when compared with patients with SRAH and con-
trol patients, whose AHI was similar. Patients with SRAH and 
those with OSA had a similar mean and minimal SatO2, but it 
was lower in comparison with control patients. WASO and the 
awakening index were higher in OSA patients, although the dif-
ferences were not statistically significant. Sleep characteristics 
of all groups are summarized in Table 2.
HRV Parameters
The ANOVA between-group analysis revealed that mean 
R-R intervals and SDNN were lower in patients with OSA 
and SRAH when compared with control patients in all sleep 
stages, although the differences did not reach statistical sig-
nificance. Across sleep stages, no significant differences were 
observed in W-pre, W-post, and N3 stages. However, during 
N1-N2 stage, HF was lower in patients with OSA and SRAH 
(P = 0.006), and the LF/HF was higher in patients with SRAH 
when compared with control patients (P = 0.014). During 
REM, LF was higher in patients with OSA and SRAH than 
in control patients (P = 0.016), as well as VLF (P = 0.030). 
Conversely, HF was lower in patients with OSA and SRAH 
(P = 0.007). The LF/HF ratio was increased in patients with 
SRAH when compared with control patients (P = 0.011) but 
not with patients with OSA. No differences were seen when 
we compared the spectral values of patients with OSA against 
those with SRAH (Figure 1). For further details, see Table S1 
in the supplemental material.
When studying the effects of sleep stage on HRV in patients 
with SRAH, the ANOVA within-group analysis only showed 
changes during REM, comprising a significant increase of ULF 
(P = 0.003), and VLF (P = 0.003) components. In patients with 
OSA, LF was higher during REM (P = 0.004) and HF was high-
er during N1-N2 (P = 0.03). In control patients, only significant 
increases in ULF (P = 0.002) during REM and in HF during 
N1-N2 (P = 0.04) were observed.
Correlation Analysis
In patients with SRAH, mean SatO2 was inversely correlat-
ed with LF during N1-N2, and LF and LF/HF during REM; it 
was positively correlated with HF during REM. Minimal SatO2 
showed a similar pattern, as it was inversely correlated with 
LF during N3, and LF and LF/HF during REM; and positively 
correlated with HF during REM. Figure 2 shows an example of 
this correlation analysis. The remaining features (BMI, AHI, 
and WASO) did not correlate in patients with SRAH with any 
of the HRV measures (Table 3).
DISCUSSION
In this work, we aimed to study HRV across sleep stages in 
a homogenous SRAH patient sample (free from medications, 
comorbidities and any other concurrent sleep related breath-
ing disorders) and to compare it with a well-matched sample 
of patients with OSA and control patients. Another of our aims 
was to investigate whether the HRV differences were correlated 
with BMI, AHI, WASO, or oxygen saturation.
Our results revealed that patients with SRAH exhibit an 
increased LF heart rate (which is thought to be dependent on 
negative feedback of the baroreflex arch mediated by both SNS 
and PNS, and traditionally has been considered a measure of 
sympathetic activity) and decreased HF heart rate (which is 
modulated by PNS inputs only), suggesting an impaired car-
diovascular tone during sleep, particularly during REM sleep, 
when compared with control patients with similar sleep struc-
ture, BMI, and AHI. Furthermore, when patients with SRAH 
were compared with a group of patients with OSA with similar 
sleep structure, BMI, mean SatO2 and minimal SatO2, no differ-
ences were observed.
Moreover, in patients with SRAH, the LF band was inverse-
ly correlated with the mean and minimal SatO2 values, but not 
with BMI or AHI. The HF band was directly correlated with the 
mean and minimal SatO2 values, but not with the BMI or the 
AHI. The influence of BMI on HRV has remained controver-
sial, with some studies finding that obese patients have changes 
in HRV,14,15 whereas other investigations found no association.7 
This discrepancy might be a consequence of the fact that those 
studies finding changes in HRV in obese patients did not mea-
Table 2—Sleep characteristic in patients with sleep related alveolar hypoventilation, patients with obstructive sleep apnea, and control patients
SRAH (n = 15) OSA (n = 15) Controls (n = 15) P
REM (%), mean ± SD 19.47 ± 8.43 21.01 ± 10.78 20.65 ± 5.37 0.89
N1-N2 stages (%) 56.16 ± 13.52 55.27 ± 8.45 58.63 ± 14.11 0.60
N3 stage (%) 24.64 ± 12.79 23.72 ± 9.44 22.12 ± 7.87 0.77
REM latency (min) 134 ± 108.35 153 ± 87.01 139.77 ± 101.54 0.86
WASO (%) 9.54 ± 10.37 14.36 ± 10.34 8.24 ± 6.16 0.17
Periodic leg movement index 0 0 0 1.00
Awakening index (nº/h) 3.94 ± 2.69 6.5 ± 4.03 5.5 ± 4.96 0.16
AHI (nº/h) 3.28 ± 1.13 32.35 ± 31.38 4.07 ± 0.43  < 0.001
Minimal SatO2 (%) 82.8 ± 3.36 82.42 ± 4.18 90.5 ± 3.12  < 0.001
Mean SatO2 (%) 94.53 ± 0.99 94.57 ± 1.34 96.45 ± 1.43 0.005
AHI, apnea-hypopnea index; OSA, obstructive sleep apnea; REM, rapid eye movement; SatO2, oxygen saturation; SD, standard deviation; SRAH, sleep 
related alveolar hypoventilation; WASO, wake after sleep onset. 
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sure oxygen saturation nor were PSGs performed, and there-
fore the possibility that patients had sleep disordered breathing 
could not be excluded.
The individual effects of intermittent hypoxia and intra-
thoracic pressure swings on the sympathetic nervous system 
activity during sleep disordered breathing are diffi cult to dis-
entangle.16 We added further insight into the pathophysiology 
of abnormal autonomic tone during sleep observed in OSA pa-
tients. Our results suggest that the increased sympathetic and 
decreased parasympathetic tone observed in patients with OSA 
and SRAH might be a direct consequence of the hypoxemia 
during sleep; acute changes in intrathoracic pressure during 
nocturnal respiratory events (i.e., apnea and hypopneas that 
give rise to intrathoracic swings) probably have a minor rele-
vance in the dysregulation of cardiac autonomic control during 
sleep in patients with sleep disordered breathing.
Some authors have underlined the importance of increased 
intrathoracic pressure swings, which are an important feature 
of OSA, in the abnormal cardiac function.17,18 Increased nega-
tive inspiratory intrathoracic pressures generated against the 
occluded upper airway increase left ventricular (LV) pressure 
and amplify LV afterload. These changes increase venous re-
turn, augmenting right ventricular (RV) preload, whereas OSA-
induced hypoxemia will result in pulmonary vasoconstriction, 
thus giving rise to an increased RV afterload. These phenomena 
(i.e., RV distension and impairment of LV fi lling) can synergisti-
cally increase myocardial oxygen demand in the context of re-
duced tissue oxygen delivery during apnea-related hypoxemia.19
Figure 1—Mean R-R interval, standard deviation of the NN interval (SDNN), ultra low-frequency components (ULF), very low-frequency components (VLF), 
low-frequency components (LF), and high-frequency components (HF) during different sleep stages (N1-N2, N3, REM) as well as during wakefulness before 
(W-pre) and after (W-post) sleep in patients with SRAH, patients with OSA, and control patients. Asterisks indicate statistical signifi cance, and the analysis of 
variance P value is given. OSA, obstructive sleep apnea; REM, rapid eye movement; SRAH, sleep related alveolar hypoventilation.
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However, our results support the importance of hypoxia 
per se, independently of other phenomena, and nicely ex-
tends the findings by Sforza et al.20 who found that, during 
REM sleep, hypoxic responsiveness does not account for the 
observed changes in intrathoracic pressure during apnea. In 
our study, autonomic disturbances were observed primarily 
during REM sleep. Additional experimental reports have em-
phasized the key role of hypoxemia in the autonomic changes 
seen in OSA.21,22
The arterial chemoreceptors, particularly the carotid bodies 
that operate as primary sensors for hypoxemia, and the ensu-
ing carotid chemoreflex trigger a reactive oxygen species-me-
diated signaling that increases sympathetic activity, elevates 
blood pressure, and stimulates breathing, giving rise to arous-
al from sleep.23 Upon arousal (which is a direct consequence 
of hypoxemia) autonomic activity, blood pressure, cardiac 
output, and heart rate rapidly increase, resulting in more in-
creased cardiac oxygen demand at a time when arterial SatO2 
is at its lowest level.24 In patients with OSA, repetitive apnea 
episodes aggravate the hypoxemia and CO2 retention, both of 
which augment sympathetic activity and reduce parasympa-
thetic activity.25,26
Our findings indicating that patients with OSA exhibit 
changes of spectral components of the HRV are mainly in ac-
cordance with previous reports showing that patients with OSA 
have a an increased sympathetic predominance, primarily dur-
ing REM sleep (where apneas and hypopneas, and also hypox-
emia, predominate).27-30 Although a similar mechanism might 
take place in patients with SRAH, the pathways by which noc-
turnal hypoxemia causes autonomic dysfunction in this popula-
tion remain unclear.
Previous experimental studies clearly support the fact that 
hypoxemia elevates sympathetic basal activity.21,25,31 Patients 
with congenital alveolar hypoventilation exhibit a decreased 
cortical thickness and extensive axonal injury as a conse-
quence of sustained hypoxia.32 It is possible that autonomic 
neurons may be able to survive prolonged periods of mild 
hypoxia, but that damage occurs following more severe hy-
poxemia, even if this lasts only for a few min. This could 
explain why HRV was correlated both with the minimal 
oxygen saturation and the mean nocturnal oxygen satura-
tion. Alhough bilevel pressure ventilation has been shown to 
improve oxygenation and sleep quality in obesity hypoven-
tilation syndrome,33 it is unknown whether the autonomic 
damage is reversible, and further studies to investigate the ef-
fects of treatment with noninvasive ventilation on autonomic 
function in patients with SRAH are required.
The similar HRV findings in patients with SRAH and those 
with OSA raises the question whether both conditions repre-
sent two stages of a clinical continuum of sleep disordered 
breathing, ranging from normality to severe OSA.34,35 This vi-
sion is supported by the fact that upper airway collapsibility 
during sleep is variable (which would help to explain why not 
all patients with severe obesity develop OSA)36,37; and by the 
fact that nonapneic snorers as well as patients with upper air-
way resistance syndrome (two of the conditions also included 
in the continuum of sleep disordered breathing) exhibit altera-
tions in HRV during sleep.38,39 However, the initiating feature 
of OSA would be the obstructive episodes leading to hypoxia 
(and, in the long-term, diminished chemoreceptor responsive-
ness24), whereas the initiating feature of SRAH (and also in 
central sleep apnea40) would be the impaired chemoreceptor 
responsiveness per se, resulting in diminished drive to breathe, 
hypoventilation, and hypoxemia.
This is the first study to analyze the HRV both in idiopathic 
and obesity-related SRAH, as previous studies have only in-
vestigated patients with congenital central hypoventilation 
syndrome8,9 and hypoventilation associated with chest wall de-
formities and neuromuscular disease.10 These previous studies, 
as with the current study, also found that autonomic dysfunction 
Figure 2—Examples of correlation analysis. Low-frequency (LF) heart rate variability during rapid eye movement (REM) sleep in relation to minimal oxygen 
saturation (SatO2) and apnea-hypopnea index (AHI). The y-axis is given in ms2. Significant increases in LF variability occurred with decreasing SatO2 
(r = -0.59; P = 0.037) but not with increasing AHI (r = -0.21; P = 0.66).
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appears to be related to the severity of oxygen desaturation, al-
though patients with less severe nocturnal oxygen desaturation 
had significant abnormalities in comparison with those with no 
oxygen desaturation.10
The observed differences of HRV in patients with SRAH 
when compared with control patients cannot be attributed to 
differences in BMI, AHI, or sleep structure, as both groups 
had similar characteristics. Remarkably, we were able to se-
lect control patients with severe obesity (BMI ≥ 30 kg/m2) 
without respiratory abnormalities, which confirms that the 
magnitude of obesity and SRAH are not sufficiently corre-
lated to predict whether an obese individual will develop sleep 
disordered breathing.
Why all patients with SRAH in our sample were found 
to be women is unclear. The main reason is probably the 
sample selection: after patients with cardiovascular and other 
comorbid diseases, patients taking drugs, and patients with 
artifacted ECG recording were excluded, only a sample com-
posed of women remained. However, epidemiology of idio-
pathic SRAH is poorly characterized, so it is not well known 
whether, in this particular condition, a female preponderance 
exists. Among patients with OHS, male patients have been 
reported to have a slightly increased frequency than wom-
en,41 although some studies have analyzed samples with more 
women than men.2
This fact is related to one of the limitations of this research: 
because all patients were female, we were unable to analyze 
the differences in HRV according to sex. This would be an in-
teresting analysis in patients with SRAH, as it has been shown 
that healthy women have a higher parasympathetic tone than 
men42 and that non-REM to REM excitatory cardiac responses 
are more marked in women that in men, regardless of their 
hormonal status.43 Hormonal mechanisms are also important, 
as women exhibit sleep disordered breathing syndrome less 
frequently than men before but not after menopause, suggest-
ing that progesterone and estrogens may exert a protective 
effect44,45 although the exact mode of action through which 
these hormones affect breathing is not completely understood. 
In our sample, the frequency of postmenopause was similar 
among the three groups, so differences could not be attributed 
to hormonal status.
Because this was a cross-sectional study, the prognostic 
value of our findings is unclear, although in other conditions, 
autonomic dysfunction as measured by HRV has been report-
ed to be a marker of morbidity and mortality.46-48 It is therefore 
likely that HRV analysis may provide a tool for prognostic 
evaluation in patients with SRAH, but this warrants additional 
prospective studies.
In conclusion, HRV is abnormal in patients with SRAH, 
and appears to be related to the severity of nocturnal oxygen 
desaturation. Moreover, there were no differences between 
patients with OSA and patients with SRAH, supporting the 
hypothesis that HRV changes seen in patients with OSA may 
be primarily related to lower nocturnal oxygen saturation 
rather than a consequence of intrathoracic changes during 
nocturnal respiratory events. Further studies are needed to 
elucidate whether the abnormal autonomic function has prog-
nostic significance, and whether it is affected by the treat-
ment of SRAH.
Table 3—Spearman correlation coefficient (rho) between different 
measures and heart rate variability parameters in patients with sleep 
related alveolar hypoventilation
W-Pre
BMI AHI MinSat MeanSat WASO
R-R 0.08 -0.001 0.01 -0.08 -0.39
SDNN -0.24 -0.39 0.23 -0.37 -0.31
ULF -0.16 -0.41 0.09 -0.15 0.19
VLF -0.41 -0.18 -0.03 0.09 0.14
LF -0.26 -0.27 -0.18 0.14 -0.21
HF -0.18 0.07 -0.09 -0.19 0.18
LF/HF 0.03 -0.16 -0.12 -0.31 -0.14
N1-N2
BMI AHI MinSat MeanSat WASO
R-R -0.06 -0.28 -0.26 -0.21 -0.51
SDNN -0.13 0.19 0.12 0.06 0.14
ULF 0.25 0.17 -0.29 -0.09 -0.06
VLF -0.1 -0.02 0.2 0.06 -0.04
LF -0.14 0.17 -0.39 -0.62a 0.05
HF -0.12 0.21 0.18 0.12 0.28
LF/HF 0.09 0.26 -0.26 -0.32 0.41
N3
BMI AHI MinSat MeanSat WASO
R-R -0.31 -0.17 -0.03 -0.14 -0.38
SDNN 0.24 -0.06 -0.41 -0.13 -0.11
ULF 0.38 0.19 -0.49 0.09 -0.15
VLF 0.12 -0.09 -0.39 0.08 -0.29
LF -0.06 -0.09 -0.55a -0.29 -0.14
HF 0.3 0.03 0.11 0.41 0.11
LF/HF 0.13 0.18 0.08 -0.08 0.23
REM
BMI AHI MinSat MeanSat WASO
R-R 0.3 0.21 -0.35 -0.55 0.21
SDNN 0.03 -0.41 -0.38 -0.25 0.12
ULF -0.01 0.36 -0.37 -0.24 0.09
VLF -0.02 0.41 -0.03 0.03 0.1
LF -0.07 -0.21 -0.59a -0.61a 0.06
HF 0.04 -0.19 0.51a 0.58a -0.03
LF/HF -0.05 0.15 -0.52a -0.51a 0.18
W-Post
BMI AHI MinSat MeanSat WASO
R-R 0.16 -0.14 0.01 0.02 0.18
SDNN 0.4 -0.21 -0.45 0.01 0.24
ULF 0.12 0.23 0.3 -0.42 -0.08
VLF 0.29 -0.16 0.07 -0.26 -0.01
LF 0.42 -0.42 0.16 -0.05 -0.38
HF 0.38 -0.27 -0.22 -0.23 -0.43
LF/HF 0.19 0.08 -0.39 -0.32 0.49
aP < 0.05. AHI, apnea-hypopnea index; BMI, body mass index; HF, high 
frequency; LF, low frequency; minSat, minimum saturation; meanSat, 
mean saturation; REM, rapid eye movement; SDNN, standard deviation 
of normal-to-normal RR interval; ULF, ultra low frequency; VLF, very low 
frequency; WASO, wake after sleep onset; W-Post; wakefulness after 
sleep; W-Pre, wakefulness before sleep. Significant values are in bold.
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SUPPLEMENTAL MATERIAL
Table S1—Heart rate variability in patients with sleep related alveolar hypoventilation, patients with obstructive sleep apnea, and control patients
W-pre
SRAH OSA Controls
R-R mean (ms), ± SD 0.77 ± 0.12 0.81 ± 0.08 0.82 ± 0.08
SDNN (ms), ± SD 0.043 ± 0.03 0.045 ± 0.018 0.049 ± 0.022
ULF (ms2), ± SD 0.000082 ± 0.00011 0.000094 ± 0.00016 0.000052 ± 0.00051
VLF (ms2), ± SD 0.000031 ± 0.000029 0.000031 ± 0.000016 0.000022 ± 0.000021
LF (ms2), ± SD 0.000022 ± 0.000027 0.000019 ± 0.000015 0.000013 ± 0.000013
HF (ms2), ± SD 0.0000068 ± 0.000014 0.0000046 ± 0.0000056 0.000023 ± 0.000017
LF/HF (ms2), ± SD 1.02 ± 0.89 1.22 ± 1.49 0.91 ± 0.92
N1-N2
SRAH OSA Controls
R-R mean (ms), ± SD 0.84 ± 0.13 0.86 ± 0.09 0.90 ± 0.08
SDNN (ms), ± SD 0.048 ± 0.03 0.042 ± 0.012 0.071 ± 0.052
ULF (ms2), ± SD 0.000071 ± 0.000082 0.000058 ± 0.000048 0.000038 ± 0.000021
VLF (ms2), ± SD 0.000051 ± 0.000054 0.000046 ± 0.000047 0.000028 ± 0.000021
LF (ms2), ± SD 0.000028 ± 0.000026 0.000022 ± 0.000034 0.000014 ± 0.000048
HF (ms2), ± SD 0.000011 ± 0.000016b 0.000013 ± 0.000018b 0.000031 ± 0.000058b 
LF/HF (ms2), ± SD 1.8 ± 1.4c 1.5 ± 1.3c 0.6 ± 0.4c
N3
SRAH OSA Controls
R-R mean (ms), ± SD 0.8 ± 0.12 0.79 ± 0.06 0.83 ± 0.11
SDNN (ms), ± SD 0.042 ± 0.022 0.037 ± 0.029 0.052 ± 0.043
ULF (ms2), ± SD 0.000035 ± 0.000046 0.000067 ± 0.00012 0.000021 ± 0.000012
VLF (ms2), ± SD 0.000016 ± 0.000012 0.000021 ± 0.000033 0.000013 ± 0.000011
LF (ms2), ± SD 0.000021 ± 0.000016 0.000017 ± 0.00002 0.000012 ± 0.0000042
HF (ms2), ± SD 0.0000062 ± 0.0000067 0.0000035 ± 0.0000046 0.000023 ± 0.000034
LF/HF (ms2), ± SD 1.3 ± 1.5 0.9 ± 1.7 1.0 ± 0.3
REM
SRAH OSA Controls
R-R mean (ms), ± SD 0.85 ± 0.15 0.87 ± 0.08 0.90 ± 0.9
SDNN (ms), ± SD 0.078 ± 0.052 0.061 ± 0.024 0.1 ± 0.08
ULF (ms2), ± SD 0.00023 ± 0.00028 0.00014 ± 0.00015 0.00014 ± 0.00012
VLF (ms2), ± SD 0.0001 ± 0.0001a 0.000058 ± 0.000062a 0.000048 ± 0.000031a
LF (ms2), ± SD 0.000035 ± 0.000027d 0.000038 ± 0.000015d 0.000018 ± 0.000022d 
HF (ms2), ± SD 0.0000076 ± 0.0000025e 0.0000056 ± 0.0000036e 0.000026 ± 0.00008e 
LF/HF (ms2), ± SD 1.6 ± 1.2f 1.1 ± 1.7f 0.24 ± 0.3f
W-post
SRAH OSA Controls
R-R mean (ms), ± SD 0.82 ± 0.11 0.84 ± 0.07 0.88 ± 0.07
SDNN (ms), ± SD 0.057 ± 0.02 0.059 ± 0.01 0.08 ± 0.11
ULF (ms2), ± SD 0.000013 ± 0.00008 0.000021 ± 0.00041 0.0000015 ± 0.00014
VLF (ms2), ± SD 0.00006 ± 0.00004 0.000048 ± 0.000042 0.000052 ± 0.000051
LF (ms2), ± SD 0.000018 ± 0.000015 0.000018 ± 0.000025 0.0000011 ± 0.000018
HF (ms2), ± SD 0.0000063 ± 0.0000067 0.0000039 ± 0.0000024 0.000018 ± 0.000091
LF/HF (ms2), ± SD 1.06 ± 1.1 1.3 ± 1.3 0.90 ± 0.91
HF, high frequency; LF, low frequency; REM, rapid eye movement; SDNN, standard deviation of normal-to-normal RR interval; SRAH, sleep related alveolar 
hypoventilation; ULF, ultra low frequency; VLF, very low frequency; W-post; wakefulness after sleep; W-pre, wakefulness before sleep. Statistically different 
values are in bold.
aP = 0.030; Bonferroni: SRAH vs. controls: P = 0.038; OSA vs. controls: P = 0.041; SRAH vs. OSA: P = 1.
bP = 0.006; Bonferroni: SRAH vs. controls: P = 0.0142; OSA vs. controls: P = 0.040; SRAH vs. OSA: P = 1.
cP = 0.014; Bonferroni: SRAH vs. OSA: P = 0.36; OSA vs. controls: P = 0.012; SRAH vs. controls: P = 0.37.
dP = 0.016; Bonferroni: SRAH vs. controls: P = 0.015; OSA vs. controls: P = 0.106 SRAH vs. OSA: P = 1.
eP = 0.007; Bonferroni: SRAH vs. controls: P = 0.014; OSA vs. controls: P = 0.030; SRAH vs. OSA: P = 1.
fP = 0.011; Bonferroni: SRAH vs. controls: P = 0.012; OSA vs. controls: P = 0.14; SRAH vs. OSA: P = 0.
